Merck’s Sac-TMT Meets OS Endpoint but Fails PFS in TroFuse-015

Share on Social Media

Gastroesophageal Cancer
Image: Pexels

Written By: Aasritha Thippavajjala, PharmD

Reviewed By: Pharmacally Editorial Team

Merck announced on November 20, 2026, that its Phase 3 TroFuse-015 trial evaluating sacituzumab tirumotecan (sac-TMT), an investigational TROP2-directed antibody-drug conjugate (ADC), met its primary endpoint of overall survival (OS) in patients with previously treated, locally advanced unresectable or metastatic gastroesophageal adenocarcinoma. Sac-TMT demonstrated a statistically significant and clinically meaningful improvement in OS compared with treatment of physician’s choice (TPC), according to the company. However, the study did not meet its secondary progression-free survival (PFS) endpoint.

The findings represent the first global Phase 3 demonstration of an OS benefit with a TROP2-directed ADC in this patient population. While the results add to the clinical evidence base for sac-TMT, the absence of disclosed numerical efficacy estimates currently limits assessment of the magnitude of the survival benefit.

TroFuse-015 Phase 3 Trial: Study Design and Treatment Approach

TroFuse-015 (NCT06356311) was a randomized, open-label, multicenter, global Phase 3 trial enrolling 473 patients with locally advanced unresectable or metastatic gastroesophageal adenocarcinoma who had received two or more prior lines of systemic therapy. The disease category includes gastric, gastroesophageal junction (GEJ) and esophageal adenocarcinomas.

Participants were randomized to receive either sac-TMT or TPC across two treatment arms.

Experimental arm:

  • Sac-TMT: 4 mg/kg intravenously on Days 1, 15 and 29 of each six-week cycle.

Control arm (TPC, four chemotherapy options):

  • Trifluridine-tipiracil: 35 mg/m² orally twice daily on Days 1–5 and 8–12 of each four-week cycle.
  • Irinotecan: 150 mg/m² intravenously on Days 1 and 15 of each four-week cycle.
  • Paclitaxel: 80 mg/m² intravenously on Days 1, 8 and 15 of each four-week cycle.
  • Docetaxel: 75 mg/m² intravenously on Day 1 of each three-week cycle.

OS served as the primary endpoint, while secondary endpoints included PFS, objective response rate (ORR) and duration of response (DOR).

Clinical Findings: Overall Survival Improvement

At the final analysis, sac-TMT demonstrated a statistically significant and clinically meaningful improvement in OS compared with TPC, meeting the primary endpoint. According to Merck, the survival findings were generally consistent across patient subgroups, irrespective of TROP2 expression status.

However, the company has not yet disclosed median OS, hazard ratios, confidence intervals or other numerical efficacy estimates. These figures will be essential for evaluating the magnitude and clinical relevance of the survival benefit.

Secondary Endpoints: PFS and Response

Despite achieving its primary endpoint, sac-TMT did not meet the secondary PFS endpoint assessed by blinded independent central review (BICR).

The treatment also demonstrated a nominal improvement in ORR compared with TPC, although this difference was not formally tested under the prespecified statistical analysis plan. Numerical response rates and detailed DOR findings have not yet been reported.

Without the complete clinical dataset, the factors underlying the difference between the OS and PFS outcomes cannot yet be established.

Safety Profile

The safety profile of sac-TMT was consistent with findings from previously reported studies, with no new safety signals observed in TroFuse-015, according to Merck. Detailed adverse-event frequencies, severity grades and treatment discontinuation rates have not yet been disclosed.

TroFuse Development Programme and Licensing Background

TroFuse-015 represents the second positive Phase 3 readout from Merck’s global TroFuse clinical development programme evaluating sac-TMT across multiple tumour types. The programme currently includes 18 ongoing global Phase 3 trials spanning more than nine disease areas and involving over 15,000 patients worldwide, with 14 of these studies pursuing first-in-class opportunities.

The programme covers endometrial, bladder, breast, cervical, gastric, non-small cell lung and ovarian cancers, among other malignancies, and evaluates sac-TMT across different disease stages as monotherapy and in combination with immunotherapies.

Originally developed by Kelun-Biotech, sac-TMT was licensed to Merck under an exclusive agreement covering development, manufacturing and commercialisation outside Greater China, comprising mainland China, Hong Kong, Macau and Taiwan.

The ADC combines a TROP2-targeting antibody with a belotecan-derived topoisomerase I inhibitor payload, connected through a bifunctional linker designed to potentially maximise payload delivery to tumour cells while minimising payload loss during circulation.

Merck plans to present the TroFuse-015 findings at an upcoming medical meeting and share the results with regulatory authorities.

Clinical Interpretation: Significance of the TroFuse-015 Findings

The TroFuse-015 results provide important Phase 3 evidence for sac-TMT in third-line and later advanced gastroesophageal adenocarcinoma, a setting where effective treatment options remain limited and unmet medical need is high. Achieving a statistically significant OS benefit in this previously treated population represents an important clinical development and supports further investigation of sac-TMT in advanced gastroesophageal malignancies.

At the same time, failure to meet the BICR-assessed PFS endpoint warrants careful interpretation alongside the OS findings. The absence of numerical efficacy estimates, including median OS and hazard ratios, currently limits assessment of the magnitude of the survival benefit. The complete clinical dataset will be important for understanding the relationship between the observed OS and PFS outcomes and establishing the overall benefit-risk profile of sac-TMT in this treatment setting.

Reference

Merck Announces TroFuse-015 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoint of Overall Survival (OS) in Third-Line or Later Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma, Merck, 20 November 2026

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/​Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) (TroFuse-015), ClinicalTrials.gov ID NCT06356311

About the Writer

Aasritha Thippavajjala (Linkedin) is a pharm D student and aspiring medical writer with medical writing, clinical training experience and a strong interest in clinical research and patient safety She has hands-on exposure to clinical pharmacy activities including medication profile assessment, clinical case review, identification of potential drug-related problems, ADR awareness, patient counselling, and clinical documentation. She has also gained experience in medical literature review, evidence synthesis, and scientific communication through her published review article on digital twin-based patient simulation and her poster presentation at the 74th Indian Pharmaceutical Congress. Certified in ICH Good Clinical Practice (E6(R3)) and Scientific Writing in Health Research, she is passionate about applying her clinical knowledge and research skills to medical writing ,clinical research and contributing to accurate, evidence-based healthcare.


Share on Social Media
Scroll to Top